Experimental Transplantation Surgery, Department of General, Visceral and Vascular Surgery, Medical Faculty at the Friedrich Schiller University Jena, University Hospital Jena, Drackendorfer Str. 1, 07747 Jena, Germany.
Histochem Cell Biol. 2012 Dec;138(6):913-24. doi: 10.1007/s00418-012-1006-4. Epub 2012 Aug 15.
In this study, we demonstrate functional expression of the proteinase-activated receptor 2 (PAR(2)), a member of a G-protein receptor subfamily in primary cholangiocarcinoma (PCCA) cell cultures. Treatment of PCCA cells with the serine proteinase trypsin and the PAR(2)-selective activating peptide, furoyl-LIGRLO-NH(2), increased migration across a collagen membrane barrier. This effect was inhibited by a PAR(2)-selective pepducin antagonist peptide (P2pal-18S) and it was also blocked with the Met receptor tyrosine kinase (Met) inhibitors SU 11274 and PHA 665752, the MAPKinase inhibitors PD 98059 and SL 327, and the Stat3 inhibitor Stattic. The involvement of Met, p42/p44 MAPKinases and Stat3 in PAR(2)-mediated PCCA cell signaling was further supported by the findings that trypsin and the PAR(2)-selective agonist peptide, 2-furoyl-LIGRLO-NH(2), stimulated activating phosphorylation of these signaling molecules in cholangiocarcinoma cells. With our results, we provide a novel signal transduction module in cholangiocarcinoma cell migration involving PAR(2)-driven activation of Met, p42/p44 MAPKinases and Stat3.
在这项研究中,我们证明了蛋白酶激活受体 2(PAR(2))在原发性胆管癌细胞培养物中的功能表达,PAR(2) 是 G 蛋白受体亚家族的成员。用丝氨酸蛋白酶胰蛋白酶和 PAR(2)选择性激活肽 furoyl-LIGRLO-NH(2)处理 PCCA 细胞可增加穿过胶原膜屏障的迁移。这种效应被 PAR(2)选择性肽激动剂拮抗剂肽 (P2pal-18S) 抑制,也被 Met 受体酪氨酸激酶 (Met) 抑制剂 SU 11274 和 PHA 665752、MAPKinase 抑制剂 PD 98059 和 SL 327 以及 Stat3 抑制剂 Stattic 阻断。胰蛋白酶和 PAR(2)选择性激动肽 2-糠酰基-LIGRLO-NH(2)刺激这些信号分子在胆管癌细胞中的激活磷酸化,进一步支持 Met、p42/p44 MAPKinase 和 Stat3 参与 PAR(2)介导的 PCCA 细胞信号转导的发现。有了我们的结果,我们提供了一个涉及 PAR(2)驱动的 Met、p42/p44 MAPKinase 和 Stat3 激活的新型胆管癌细胞迁移信号转导模块。